ERBB2 and neoplasm: These differences are centered on cell-cycle and molecular drivers expressed by tumor cells (HER2, p53, and Ki67), phenotypic attributes (high differentiation grade, SRC content, and MUC6 expression), and microenvironment features (FOXP3 and PD-L1).